Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington's Disease (HD).
Prosensa's portfolio of clinical and pre-clinical RNA-based drug candidates is currently focused on the treatment of DMD, with 6 programs currently in development. Prosensa’s lead candidate for the treatment of DMD, drisapersen, has completed Phase III clinical trials.
Prosensa commenced operations in 2002 and is located in Leiden, The Netherlands. The company works closely together with academia, patient groups and experts worldwide.
View all » Recent Releases
Nov 24, 2014
BioMarin and Prosensa Holding N.V. Reach Agreement on Intended Public Offer for 100% of Prosensa's Outstanding Stock; Will Add Duchenne Muscular Dystrophy Products to Rare-Disease Portfolio
View all »Events & Presentations
Jan 13, 2015 at 2:00 PM CET
Prosensa Extraordinary General Meeting of Shareholders
- Investor Relations
- Company Overview